A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Olmesartan medoxomil and hydrochlorothiazide in Essential Hypertension, sponsored by Takeda. Completed at 26 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-12.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 6th largest by enrollment, is one of 3 that started in 2009, is one of 10 in phase 3, and was the 8th registered.
481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.
Browse Essential Hypertension studies →None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2009.
This study's enrollment of 837 is above the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 837 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Essential Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Essential Hypertension by Takeda, this one is the 7th largest by enrollment, is one of 3 that started in 2009, is one of 12 in phase 3, and was the 8th registered.
Takeda’s Essential Hypertension studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 15 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone, once daily (QD), versus olmesartan medoxomil-hydrochlorothiazide in adults with essential hypertension.
High Blood Pressure (Hypertension) is the most common cause of preventable death in developed nations. Uncontrolled hypertension greatly increases the risk of heart disease, brain disease, and kidney failure. As the population ages, the incidence of hypertension will continue to increase if effective preventive measures are not implemented. Despite the availability of antihypertensive agents, hypertension is not adequately controlled; only about one in three patients successfully keep blood pressure normal.
Treatment for high blood pressure includes thiazides or thiazide-like diuretics, either alone or as part of combination treatment. Chlorthalidone is a commercially available, orally administered thiazide-type diuretic agent.
TAK-491 (azilsartan) is an angiotensin II receptor blocker being evaluated by Takeda to treat patients with high blood pressure (essential hypertension).
This study will compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone (TAK-491CLD) fixed-dose combination to olmesartan medoxomil-hydrochlorothiazide fixed-dose combination.
Initially patients will undergo a Screening Visit to confirm that they are eligible to participate in the study. All participants will receive the study drug for up to 52 weeks. The dose of the study drug may be gradually increased throughout the study so that a target blood pressure value can be reached for each participant.
Throughout the treatment period of the study, participants will be required to visit the research site for 11 visits. At these study visits participants will be required to undergo certain study procedures including physical examinations, vital sign measurements (blood pressure, heart rate, weight and height), electrocardiograms (monitoring of the heart), and blood and urine samples taken for clinical laboratory tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Is taking or expected to take any excluded medication, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of azilsartan medoxomil 80 mg and chlorthalidone 25 mg.
Drug: Azilsartan medoxomil and chlorthalidone
Participants in the United States: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg. Participants in Europe: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg.
Drug: Olmesartan medoxomil and hydrochlorothiazide
Drug pages: Azilsartan medoxomil · Chlorthalidone
Combination tablet.
Also known as: TAK-491CLD
Drug pages: Olmesartan Medoxomil · Hydrochlorothiazide
Combination tablet.
Also known as: Benicar HCT®, Olmetec Plus®
Percentage of Participants With at Least 1 Adverse Event
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product without regard to causality.
Time frame: From Week 0 (Day 1) to Week 52.
Percentage of Participants With Serum Creatinine Elevations Greater Than 50% From Baseline and Greater Than the Upper Limit of Normal (ULN)
Serum creatinine was measured at every visit and evaluated as a laboratory parameter of special interest. The percentage of participants with creatinine increase ≥50% from Baseline and greater than ULN was summarized: - At any visit (includes transient and persistent elevations). - At the Final Visit (includes persistent elevations and participants whose first elevation may have been at the Final Visit). - At least 2 consecutive visits (includes only persistent elevations).
Time frame: Baseline and Week 52
Participants took part in the study at 79 investigative sites in the United States, Netherlands, Poland, the United Kingdom and Germany from 27 October 2009 to 17 November 2011.
| Milestone | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide |
|---|---|---|
| Started | 418 | 419 |
| Completed | 287 | 330 |
| Not completed | 131 | 89 |
| Withdrew: Adverse event | 75 | 37 |
| Withdrew: Major protocol deviation | 6 | 7 |
| Withdrew: Lost to follow-up | 14 | 16 |
| Withdrew: Withdrawal by subject | 31 | 20 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Other | 5 | 7 |
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product without regard to causality.
| percentage of participants | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide |
|---|---|---|
| Percentage of Participants With at Least 1 Adverse Event | 78.5 | 76.4 |
Serum creatinine was measured at every visit and evaluated as a laboratory parameter of special interest. The percentage of participants with creatinine increase ≥50% from Baseline and greater than ULN was summarized: - At any visit (includes transient and persistent elevations). - At the Final Visit (includes persistent elevations and participants whose first elevation may have been at the Final Visit). - At least 2 consecutive visits (includes only persistent elevations).
| percentage of participants | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide |
|---|---|---|
| At any postbaseline visit | 14.2 | 5.8 |
| at the Final Visit | 5.9 | 1.0 |
| ≥2 consecutive elevations | 5.1 | 1.2 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azilsartan Medoxomil and Chlorthalidone | — | 24/418 (5.7%) | 217/418 (51.9%) |
| Olmesartan Medoxomil and Hydrochlorothiazide | — | 26/419 (6.2%) | 183/419 (43.7%) |
| Event | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide |
|---|---|---|
| Septic shockInfections and infestations | 2/418 | 0/419 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 2/418 | 0/419 |
| SyncopeNervous system disorders | 2/418 | 0/419 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/418 | 0/419 |
| Angina pectorisCardiac disorders | 0/418 | 2/419 |
| Non-cardiac chest painGeneral disorders | 1/418 | 2/419 |
| PneumoniaInfections and infestations | 0/418 | 2/419 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/418 | 2/419 |
| Blood creatinine increasedInvestigations | 0/418 | 2/419 |
| Atrial fibrillationCardiac disorders | 1/418 | 1/419 |
| Event | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide |
|---|---|---|
| Blood creatinine increasedInvestigations | 90/418 | 35/419 |
| DizzinessNervous system disorders | 68/418 | 53/419 |
| NasopharyngitisInfections and infestations | 51/418 | 48/419 |
| HeadacheNervous system disorders | 31/418 | 46/419 |
| Upper respiratory tract infectionInfections and infestations | 20/418 | 27/419 |
| FatigueGeneral disorders | 21/418 | 17/419 |
| DiarrhoeaGastrointestinal disorders | 20/418 | 21/419 |
| NauseaGastrointestinal disorders | 20/418 | 21/419 |
| Age Continuous(years) | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide | Total |
|---|---|---|---|
| Mean | 58.5 ± 10.79 | 57.6 ± 10.80 | 58.1 ± 10.80 |
| Age, Customized(participants) | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide | Total |
|---|---|---|---|
| <45 years | 46 | 48 | 94 |
| 45 to 64 years | 251 | 259 | 510 |
| 65 to 74 years | 94 | 93 | 187 |
| ≥75 years | 27 | 19 | 46 |
| Sex: Female, Male(Participants) | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide | Total |
|---|---|---|---|
| Female | 192 | 173 | 365 |
| Male | 226 | 246 | 472 |
| Race/Ethnicity, Customized(participants) | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide | Total |
|---|---|---|---|
| Hispanic or Latino | 40 | 41 | 81 |
| Non-Hispanic or Latino | 209 | 205 | 414 |
| Not collected | 169 | 172 | 341 |
| Missing | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 5 | 9 |
| Asian | 4 | 7 | 11 |
| Black or African American | 72 | 74 | 146 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 341 | 336 | 677 |
| Multiracial | 3 | 3 | 6 |
| Region of Enrollment(participants) | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide | Total |
|---|---|---|---|
| Poland | 52 | 54 | 106 |
| United States | 249 | 247 | 496 |
| Netherlands | 56 | 58 | 114 |
| Germany | 22 | 21 | 43 |
| United Kingdom | 39 | 39 | 78 |
| Height(cm) | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide | Total |
|---|---|---|---|
| Mean | 169.9 ± 10.2 | 169.6 ± 10.1 | 169.8 ± 10.1 |
| Weight(kg) | Azilsartan Medoxomil and Chlorthalidone | Olmesartan Medoxomil and Hydrochlorothiazide | Total |
|---|---|---|---|
| Mean | 91.00 ± 21.025 | 92.00 ± 21.727 | 91.50 ± 21.373 |
7 further baseline measures are reported on the registry.
The record gives a start of Oct 2009, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year after primary completion. A results delay was requested in Jan 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone